Entia Biosciences Announces Participation at the 2015 National Investment Banking Association (NIBA) Conference in Newport Beach California June 24 – 26th

SHERWOOD, OR / ACCESSWIRE / June 23, 2015 / Entia Biosciences, Inc. (OTCQB: ERGO), today announced it will be featured as a presenting company at the 2015 National Investment Banking Association (NIBA) investment conference. The conference is being held June 24 – 26th, at the Balboa Bay Resort in Newport Beach, California.

Marvin S. Hausman MD, CEO, will provide an overview of the Company’s business during the live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.

If you are an institutional investor, and would like to attend the Company’s presentation, please click on the following link www.nibanet.org to register for the NIBA conference. 

About Entia Biosciences, Inc.

Entia is an authority on the clinical effects of oxidative stress and free radical reactions and is bringing this expertise to the fields of food science biotechnology and Nutrigenomics. The Company identifies, scientifically validates, patents, and commercializes solutions that address multi-billion dollar markets for health, beauty and agriculture.

About National Investment Banking Association (NIBA)

National Investment Banking Association (NIBA) is a national trade association of regional and independent brokerages, investment banking firms, fund managers and related capital market service providers. The mission of NIBA is to add value to its members, their client companies and investors, and the securities industry at large by continuing to be the premier forum for quality micro-cap/small-cap companies seeking access and exposure to the financial community and to enhance the financial environment for small companies. NIBA Conferences are must attend events providing unique opportunities to make valuable industry connections while gaining new perspectives on critical market challenges, issues and trends redefining today’s dynamic and ever-evolving capital formation markets. Each event showcases private and public companies actively seeking access to the financial industry. Companies first present formally to hundreds and then have the opportunity to meet privately and have in-depth discussions with interested parties. NIBA member firms have completed over 1,500 equity offerings totaling approximately $12 billion in new capital for emerging growth companies. The member firms of NIBA represent over 8,800 registered representatives with an estimated $86 billion in assets under management, and are responsible for 90% of all initial public offerings under $20 million. For more information, please visit our website www.nibanet.org. You can also follow NIBA updates on Twitter @NIBAnet.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Entia Biosciences with the Securities and Exchange Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year ended December 31, 2014 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

CONTACT:

For more information, please visit our website at www.entiabio.com or contact:

Marvin Hausman, CEO
Entia Biosciences, Inc.
13565 SW Tualatin-Sherwood Rd Sherwood, OR, 97140
Phone: 503-334-3575, Email: info@entiabio.com

SOURCE: Entia Biosciences, Inc.

ReleaseID: 430074